Select: All | None

Select: All | None

Select: All | None

DIBENZYLPHENYL COMPOUNDS AND METHODS FOR THEIR USE

British Columbia Cancer Agency, University of British Columbia

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, R1 and R2 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

HEPATITIS C VIRUS E1/E2 HETERODIMERS AND METHODS OF PRODUCING SAME

University of Alberta

The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) El polypeptide and an HCV E2 polypeptide, where one or both of the El and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers,...

METHODS AND COMPOSITIONS FOR MUSCULAR DYSTROPHIES

SANGAMO BIOSCIENCES, University of Montreal

Methods and compositions for editing of genes involved in muscular dystrophies.

VACCINE AGAINST CLOSTRIDIUM PERFRINGENS

University of Guelph

There is provided a vaccine for controlling Clostridium perfringens in an imals, and particularly necrotic enteritis in poultry. The vaccine may compr ise a C. perfringens antigenic polypeptide or variant thereof, a nucleic aci d encoding the C. perfringens antigenic polypeptide or variant thereof, or a recombinant cell producing the C. perfringens antigenic polypeptide or vari ant thereof.

A method of diagnosing an asthma disease state

University of Alberta

There is provided. a method of diagnosing an asthma disease state in a subject comprising (a) providing an urine sample, (b) measuring he concentration of certain metabolites in the sample, (c) providing a concentration profile differentiating between a chronic stable asthma disease state, an exacerbated disease state, and non-disease state using respective associated concentration profile values of said metabolites and (d) comparing the concentration values with the associated concentration...

HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF

University of Alberta

The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition...

14-3-3 ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF ARTHRITIS

MAKSYMOWYCH, WALTER, WOLODYMYR, PETER, University of British Columbia

Methods for treating arthritis comprising 14-3-3 antagonists that are capable of specifically binding to extracellularly localized 14-3-3 eta and/or 14-3-3 gamma protein isoforms are provided. In preferred embodiments, the 14-3-3 antagonist is an inhibitory peptide or an anti-14- 3-3 antibody. The 14-3-3 antagonists are also formulated in a pharmaceutical composition and used in a method for reducing matrix metalloprotease (MMP) expression in the synovial fluid of a patient, wherein the MMP...

NOVEL MINOR HISTOCOMPATIBILITY ANTIGENS AND USES THEREOF

THE UNIVERSITE DE MONTREAL, University of Montreal

Minor histocompatibility antigens (MiHAs) binding to certain human leukocyte antigen (HLA) alleles are described. These MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these MiHAs are also described. The present application also discloses the use of these MiHAs, and related compositions, nucleic acids and cells, in...

HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

University of Alberta

The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a "T-cell epitope polypeptide" or an "HCV T-cell epitope polypeptide") comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or...

NOVEL MINOR HISTOCOMPATIBILITY ANTIGENS AND USES THEREOF

RSEM, LIMITED PARTNERSHIP, University of Montreal

Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer...